Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
After being approved by the Food and Drug ... could delay getting the flu shot til late October or so to ensure that you have immunity for most of the flu season,” she said. The RSV vaccine ...
The CDC recommends that everyone 6 months old and older get the updated COVID-19 vaccination, which was authorized for distribution by the U.S. Food and Drug ... The RSV vaccine is not annual ...
GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...
RSV vaccination was defined as receipt of the vaccine 14 days or more before illness onset and status was determined ... relationships with the CDC, FDA, Syneos Health, NIH, and the Agency for ...
Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...
With the arrival of new vaccines for respiratory syncytial virus (RSV), Canadian seniors are faced with a critical decision: Is it worth getting ... While vaccinating all seniors regardless of ...